Get the Stockscreener App
6.205
0.89%
0.015
After Hours:
6.15
-0.055
-0.89%
Vanda Pharmaceuticals Inc stock is traded at $6.205, with a volume of 759.99K.
It is up +0.89% in the last 24 hours and down -9.36% over the past month.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
See More
Previous Close:
$6.19
Open:
$6.2
24h Volume:
759.99K
Relative Volume:
0.33
Market Cap:
$373.14M
Revenue:
$216.11M
Net Income/Loss:
$-220.47M
P/E Ratio:
-1.6607
EPS:
-3.7363
Net Cash Flow:
$-110.44M
1W Performance:
+4.26%
1M Performance:
-9.36%
6M Performance:
+17.83%
1Y Performance:
+44.23%
1-Day Range:
$6.12
$6.31
1-Week Range:
$6.01
$6.31
52-Week Range:
$4.14
$9.94
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Name
Vanda Pharmaceuticals Inc
Sector
Industry
Phone
202-734-3400
Address
2200 PENNSYLVANIA AVE NW, WASHINGTON
Compare VNDA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
6.205 | 372.24M | 216.11M | -220.47M | -110.44M | -3.7363 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-26 | Initiated | Truist | Buy |
| Nov-05-25 | Initiated | B. Riley Securities | Buy |
| Oct-31-24 | Initiated | H.C. Wainwright | Buy |
| Jul-11-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-22 | Downgrade | Jefferies | Buy → Hold |
| May-12-21 | Initiated | BofA Securities | Buy |
| Jan-14-21 | Downgrade | Citigroup | Buy → Neutral |
| Oct-29-20 | Upgrade | Citigroup | Neutral → Buy |
| Jun-09-20 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-20 | Downgrade | Oppenheimer | Perform → Underperform |
| Mar-12-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-19 | Downgrade | Citigroup | Buy → Neutral |
| Aug-01-19 | Upgrade | Citigroup | Neutral → Buy |
| Jul-25-19 | Downgrade | Stifel | Buy → Hold |
| Dec-11-18 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-04-18 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Dec-04-18 | Reiterated | Jefferies | Buy |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Sep-21-18 | Resumed | Oppenheimer | Outperform |
| May-23-18 | Initiated | Citigroup | Buy |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Sep-14-17 | Reiterated | Piper Jaffray | Overweight |
| Jun-27-17 | Resumed | Piper Jaffray | Overweight |
| May-26-17 | Initiated | H.C. Wainwright | Buy |
| Apr-12-17 | Initiated | Oppenheimer | Outperform |
| Nov-09-16 | Initiated | Aegis Capital | Buy |
| Oct-06-16 | Resumed | Jefferies | Buy |
View All
Vanda Pharmaceuticals Inc Stock (VNDA) Latest News
Vanda a new buy at B. Riley on 'historic discount' - MSN
Vanda Pharmaceuticals Q3 Earnings Preview - MSN
Vanda (VNDA) director donates 25,836 shares of common stock - Stock Titan
VNDA: 2026 revenue guidance raised on new launches, with BYSANTI and NEREUS set to drive future growth - TradingView
How The Vanda Pharmaceuticals (VNDA) Investment Story Is Shifting With BYSANTI And Nereus - Yahoo Finance
Vanda Pharmaceuticals stock (US92178N1054): Regulatory setback, sharp drop and rising short interest - AD HOC NEWS
Vanda: A Long-Term Pharma Growth Idea, Despite Q1 Earnings Miss (NASDAQ:VNDA) - Seeking Alpha
Vanda targets $240M-$290M 2026 revenue as it introduces $10M-$30M NEREUS sales outlook - MSN
HC Wainwright Brokers Lower Earnings Estimates for VNDA - MarketBeat
State Street (VNDA) discloses 3.02M shares, 5.1% ownership on 13G - Stock Titan
Earnings call transcript: Vanda Pharmaceuticals Q1 2026 misses EPS forecast, stock drops By Investing.com - Investing.com South Africa
Earnings call transcript: Vanda Pharmaceuticals Q1 2026 misses EPS forecast, stock drops - Investing.com Nigeria
H.C. Wainwright cuts Vanda Pharmaceuticals stock price target on higher costs - Investing.com UK
H.C. Wainwright Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Cuts Target Price to $21 - Moomoo
VNDA Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
HC Wainwright Cuts Vanda Pharmaceuticals (NASDAQ:VNDA) Price Target to $21.00 - MarketBeat
H.C. Wainwright cuts Vanda Pharmaceuticals stock price target on higher costs By Investing.com - Investing.com South Africa
Vanda Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
VNDA SEC FilingsVanda Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences - BioSpace
Vanda Pharmaceuticals (VNDA) Losses Deepen To US$239.5 Million LTM Reinforcing Bearish Narratives - Sahm
VNDA Reports Strong Q1 Growth with New Product Launches - GuruFocus
VNDA Projected Revenue Forecast for 2026 at $258.2 Million - GuruFocus
Vanda Pharmaceuticals 1Q Loss/Shr 82c >VNDA - Moomoo
Vanda Pharmaceuticals to Participate in Upcoming Investor Conferences - Intellectia AI
Truist Financial Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Announces Target Price $18 - Moomoo
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q1 2026 Earnings Call Transcript - Insider Monkey
[10-Q] Vanda Pharmaceuticals Inc. Quarterly Earnings Report - Stock Titan
Vanda Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance
Vanda: Q1 Earnings Snapshot - theheraldreview.com
Vanda maps out 3 May investor events, including a live webcast - Stock Titan
MSN Money - MSN
Earnings call transcript: Vanda Pharmaceuticals misses Q1 2026 forecasts, stock rises By Investing.com - Investing.com South Africa
Vanda Pharmaceuticals Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Vanda Pharmaceuticals misses Q1 2026 forecasts, stock rises - Investing.com Nigeria
Vanda (VNDA) Q1 2026 Earnings Call Transcript - The Globe and Mail
Document - SEC.gov
VANDA PHARMACEUTICALS INC (NASDAQ:VNDA) Misses Q1 2026 Estimates as Top-Line Growth Slows - ChartMill
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Vanda Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
VANDA PHARMACEUTICALS ($VNDA) Releases Q1 2026 Earnings - Quiver Quantitative
Q1 2026 Vanda Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Vanda Pharmaceuticals (NASDAQ: VNDA) boosts 2026 revenue view on new approvals - Stock Titan
Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results - marketscreener.com
Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results – Company Announcement - Financial Times
[EFFECT] Vanda Pharmaceuticals Inc. SEC Filing - Stock Titan
How many employees work at Vanda Pharmaceuticals? - reveliolabs.com
Vanda Pharmaceuticals Inc. Raises Revenue Guidance for the Full-Year 2026 - marketscreener.com
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026 - Quantisnow
Vanda Pharmaceuticals Inc Stock (VNDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vanda Pharmaceuticals Inc Stock (VNDA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Moran Kevin Patrick | SVP, CFO & Treasurer |
Mar 02 '26 |
Sale |
8.27 |
42,442 |
350,821 |
411,380 |
| Wijkstrom Joakim | SVP, Chief Marketing Officer |
Mar 02 '26 |
Sale |
8.27 |
30,800 |
254,590 |
333,469 |
| Polymeropoulos Mihael Hristos | President and CEO |
Mar 02 '26 |
Sale |
8.17 |
156,235 |
1,276,971 |
2,704,496 |
| Birznieks Gunther | SVP, Business Development |
Mar 02 '26 |
Sale |
8.27 |
42,431 |
350,730 |
494,197 |
1.49%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):